InsidersTradesSigma
Track the 에스케이바이오팜 stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 에스케이바이오팜 has published 5 public disclosures. Market capitalisation: €6,312bn. The latest transaction was disclosed on 31 August 2026 (Purchase). Among the most active insiders: SK. All data is accessible without an account.
5
Insider Decl.
n/a
Thresholds
€719m
3 ops.
Buy Volume
n/a
1 ops.
Sell Volume
18Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 6,168 of 29,062 companies
66.0
score / 100
Value39
Quality93
FCF yld2.2%
Earn yld3.9%
EV/EBITDA39.1x
ROE48%
Gross mgn94%
Net mgn38%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 August 2026
关于 에스케이바이오팜
SK Biopharmaceuticals 是一家健康和制药领域的公司，在 XKRX 交易所上市。它专注于开发神经系统疾病的创新疗法。